About Blueprint
At Blueprint Bioconsulting, we transform complexity into clarity, empowering biotech innovators to advance groundbreaking drug discoveries that change lives.
Mission
To empower biotech companies with expert guidance and strategic insights, accelerating the discovery and development of transformative therapeutics that improve lives worldwide
Values
We value innovation, integrity, and collaboration, delivering excellence and impactful solutions to accelerate life-changing biotech advancements. Our commitment is to support clients with strategic guidance that drives transformative discoveries.
Dr. Yu (Rebecca) Miao, founder of Blueprint Bioconsulting, is a Stanford-trained biologist with over 20 years of extensive experience in therapeutic research and development, as well as in vivo and in vitro pharmacology. As a visionary leader and expert in drug discovery, she has successfully advanced therapeutic pipelines from the earliest stages of discovery to Phase III clinical development, demonstrating her ability to deliver innovative, commercially viable solutions to the biotech and pharmaceutical sectors.
Dr. Miao’s work includes co-inventing over 30 U.S. and global patent applications and spearheading the development of a proprietary protein engineering platform that has yielded multiple first-in-class and best-in-class biologic therapeutics. Transforming cutting-edge science into therapeutic programs that address critical unmet needs in oncology, autoimmune diseases, fibrosis, and rare disorders. She has also played a pivotal role in securing strategic licensing agreements and partnerships, including alliance with leading pharmaceutical companies, by leading scientific negotiations, and managing rigorous due diligence processes.
With a proven track record in securing non-dilutive funding, preparing IND-enabling packages, and facilitating FDA regulatory filings, Dr. Miao offers expertise in regulatory strategy, intellectual property management, and strategic partnership development. She is adept at identifying novel therapeutic targets, aligning development milestones with clinical roadmaps, and collaborating with CROs to deliver high-quality preclinical and clinical data.
Through Blueprint Bioconsulting, Dr. Miao brings her wealth of knowledge to support her clients, offering tailored solutions in scientific due diligence, pipeline development, and scientific partnership strategy. Her commitment to advancing transformative therapies from concept to commercialization enables her clients to achieve scientific excellence, regulatory success, and significant market impact.